Research programme: anti-cancer immunotherapies - Nouscom

Drug Profile

Research programme: anti-cancer immunotherapies - Nouscom

Alternative Names: Neoantigen vaccines; NOUS 100 PV; NOUS 209; NOUS THV 001; Oncolytic antigenless vaccines

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nouscom
  • Class Antineoplastics; Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 May 2018 NousCom plans clinical studies of NOUS 100 PV for Cancer in 2019
  • 13 Nov 2017 Preclinical data for Cancer released by NousCom
  • 09 Nov 2017 Preclinical trials in Cancer in Switzerland (unspecified route), before November 2017 (Nouscom pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top